Procaps Group SA

Procaps Group SA is an international healthcare and pharmaceutical company. The firm is engaged in the developing of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. It operates through the following segments: NextGel, Procaps Colombia, CAN, CASAND, and Diabetrics. The NextGel segment is involved in the manufacturing and distribution of prescription and over-the-counter pharmaceutical products in USA, Brazil, and Colombia. The Procaps Colombia segment is focused on the manufacturing and distribution of prescription and over-the-counter pharmaceutical products in Colombia. The CAN segment deals with the manufacturing and distribution of prescription and over-the-counter pharmaceutical products in Northern Central America: Salvador, Guatemala, Nicaragua, and Honduras. The CASAND segment offers pharmaceutical products in Southern Central America that include Panama and Costa Rica, and the North Andes District that include Ecuador, Peru, and Bolivia. The Diabetrics segment consists of the diabetes solutions and chronic disease management tool. The company was founded by Ruben Minski in 1977 and is headquartered in Luxembourg.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group to Report Second Quarter and First Half 2023 Results and Host Conference Call on Tuesday.

Procaps Group to Report Second Quarter and First Half 2023 Results and Host Conference Call on Tuesday

MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group Publishes White Paper on Innovative Gummy Technology.

Procaps Group Publishes White Paper on Innovative Gummy Technology

B2Gold

Butler National Corporation

Globalstar

GEE Group

Jerash holdings (US) Inc

PaySign Inc

Bottom-fishers, take note: there are scores of penny stock opportunities out there. While major stocks have been on a year so far this year, penny stocks (or stocks trading for $5 per share or less) have delivered a more mixed performance.

7 Penny Stocks Nearing Super Attractive Entry Points

Constant Currency Net Revenues Increased 10% Quarter-over-Quarter in 1Q23, and 22% increase in Adjusted EBITDA, With Strong Demand of RX and Softgel Portfolios, Offset by Clinical Specialty Covid Portfolio Constant Currency Net Revenues Increased 10% Quarter-over-Quarter in 1Q23, and 22% increase in Adjusted EBITDA, With Strong Demand of RX and Softgel Portfolios, Offset by Clinical Specialty Covid Portfolio

Procaps Group Reports First Quarter 2023 Results

MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group Reports Fourth Quarter and Full Year 2022 Results.

Procaps Group Reports Fourth Quarter and Full Year 2022 Results

MIAMI and BARRANQUILLA, Colombia, May 01, 2023 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced today that it will file its Form 20-F and publish its Full Year 2022 Earnings Release before May 15th.

Financial Results and Business Update Conference Call to be Held May 2023 in Conjunction with 20-F Filing

Reports Preliminary Financial Estimates for Net Revenue and Adjusted EBITDA for Full Year 2022

Procaps Issues Shareholder Letter and Provides Preliminary Fiscal Year 2022 Financial Results and 2023 Guidance

International Corporate Executive and Attorney Alberto Eguiguren Correa Appointed to Board of Directors International Corporate Executive and Attorney Alberto Eguiguren Correa Appointed to Board of Directors

Procaps Announces Key Changes to the Board of Directors

Company to Provide 2023 Value Creation Plan at J.P. Morgan Healthcare Conference Company to Provide 2023 Value Creation Plan at J.P. Morgan Healthcare Conference

Procaps Group Announces Termination of Acquisition Agreement with Grupo Somar

MIAMI and BARRANQUILLA, Colombia, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today announced that it will present at the 2023 J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 8:00 am PST. At that time, Procaps will present its 2023 growth plans to investors.

Procaps to Present at 2023 Annual J.P. Morgan Healthcare Conference

MIAMI and BARRANQUILLA, Colo., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announces an update on its previously reported definitive agreement, dated as of May 16, 2022 (the “SPA”), to acquire Grupo Somar (including Grupo Farmacéutico Somar, S.A.P.I de C.V., Química y Farmacia S.A. de C.V., Gelcaps Exportadora de Mexico S.A. de C.V. and related entities) from the sellers under the SPA (the “Sellers”).

Update on Proposed Acquisition of Grupo Somar

Procaps Group, S.A. (NASDAQ:PROC ) Q3 2022 Earnings Conference Call November 16, 2022 4:00 PM ET Company Participants Melissa Angelini - IR, Director Ruben Minski - Founder, Chief Executive Officer and Director Patricio Vargas - Chief Financial Officer Conference Call Participants Kemp Dolliver - Brookline Capital Markets Operator Good day and welcome to the Procaps Group Business Update Call and Webcast.

Procaps Group, S.A. (PROC) Q3 2022 Earnings Call Transcript

Constant currency Net Revenues Increased by 15% year-over-year in the 9M22 and by 11% in the 3Q22, signaling a strong demand across our businesses Constant currency Net Revenues Increased by 15% year-over-year in the 9M22 and by 11% in the 3Q22, signaling a strong demand across our businesses

Procaps Group Reports Third Quarter and Nine Months 2022 Results

MIAMI and BARRANQUILLA, Colombia, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced that it expects to report its results for the third quarter ended September 30, 2022, after the market closes on Monday, November 14, 2022.

Procaps Group to Report Third Quarter and Nine Months of 2022 on November 14, 2022

MIAMI and BARRANQUILLA, Colombia, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today announced the completion of its inaugural 2021 ESG Annual Report, a comprehensive overview of environmental, social and governance metrics and corresponding strategies and initiatives for ESG priorities.

Procaps Announces ESG Commitments and Initiatives with Inaugural Report

MIAMI and BARRANQUILLA, Colombia, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today announced it will participate in the BTG Pactual LatAm CEO Conference being held at the InterContinental NY Barclays Hotel October 11-13, 2022.

Procaps Group to Participate in the BTG Pactual LatAm CEO Conference

Net Revenues Increased 14% year-over-year in the Second Quarter, with Adjusted EBITDA Margin of 24% Constant currency Net Revenues Increased by 18% year-over-year in the First Half, signaling a strong demand across our businesses

Procaps Group Reports Second Quarter and First Half 2022 Results

Net Revenues Increased by 11% to U$ 86 million, with Adjusted EBITDA Up 15% Year-Over-Year to $9 Million Net Revenues Increased by 11% to U$ 86 million, with Adjusted EBITDA Up 15% Year-Over-Year to $9 Million

Procaps Group Reports Preliminary First Quarter 2022 Results

This acquisition reaffirms Procaps Groups' strategy to become one of the fastest growing pharmaceutical organizations in Latin America

Procaps Group to Acquire Grupo Somar (including Química y Farmacia, Gelcaps and related entities) from Advent International, gaining an important presence in Mexico, the Region's Second Largest Market

MIAMI--(BUSINESS WIRE)--Procaps Group Reports Fourth Quarter and Fiscal Year 2021 Financial Results

Procaps Group Reports Fourth Quarter and Fiscal Year 2021 Financial Results

MIAMI--(BUSINESS WIRE)--Procaps Group Announces Capacity Expansion Plans in the United States with Construction of New Gummy Manufacturing Facility in Florida

Procaps Group Announces Capacity Expansion Plans in the United States with Construction of New Gummy Manufacturing Facility in Florida

BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group Announces Appointment of Melissa Angelini as Investor Relations Director

Procaps Group Announces Appointment of Melissa Angelini as Investor Relations Director

BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group Acquires 1st U.S.-Based Softgel Production Facility and Pharmaceutical R&D Center to Expand Global Growth of its iCDMO Business Unit

Procaps Group Acquires 1st U.S.-Based Softgel Production Facility and Pharmaceutical R&D Center to Expand Global Growth of its iCDMO Business Unit

Procaps Group, S.A. (PROC) CEO Ruben Minski on Q3 2021 Results - Earnings Call Transcript

BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group Reports Record Third Quarter 2021 Financial Results

News for Procaps Group SA Stock (PROC)